ACT Capital Partners, L.P.’s Corvus Pharmaceuticals CRVS Stock Holding History

ACT Capital Partners, L.P.’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$311K	Buy	+27,000	New	+$376K	0.2%	43

Other funds holding CRVS

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

DCF Advisers Greenwich, Connecticut $444M AUM 151.5% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

TowerView LLC New York $137M AUM 15.24% 1-Year Est. Return

ACT Capital Partners, L.P.'s CRVS Position: Q3 2026 in Review

ACT Capital Partners, L.P. opened a new position in Corvus Pharmaceuticals (CRVS) in Q3 2026: 27,000 shares worth $311K. The stake represents 0.2% of the portfolio and ranks #43 among its holdings.

57 funds tracked by Wall St. Rank hold CRVS as of Q3 2026.

ACT Capital Partners, L.P. held 27,000 shares of Corvus Pharmaceuticals worth $311K as of Q3 2026.
Corvus Pharmaceuticals was a new ACT Capital Partners, L.P. position in Q3 2026.
Corvus Pharmaceuticals made up 0.2% of ACT Capital Partners, L.P.'s portfolio in Q3 2026, its #43 holding.
57 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2026.

Based on ACT Capital Partners, L.P.'s 13F filing for Q3 2026, filed 6 Nov 2026.